Biogen Inc. (BIIB) stock
Close on Nov 13, 2026Market cap $37.46BP/E 108.3Yield –
Biogen Inc. grew revenue 2.3% to $10.30B over the twelve months to Sep 30, 2026. Free cash flow was $2.07B, down 10.1% from a year earlier. At the latest close the market valued the company at $37.46B, 108.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $37.46B
- P/E ratio
- 108.3
- Price to sales
- 3.64
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 5.53%
Fundamentals
- Revenue
- $10.30B
- Net income
- $347.50M
- EPS, diluted
- $2.34
- Free cash flow
- $2.07B
- Diluted shares
- 148M
Trading
- Next earnings
- Jan 13, 2027 (estimated, after the close)
- Previous close
- $250.48
- Open
- $250.58
- Day's range
- $249.52 – $255.04
- Volume
- 1,028,943
- Average volume (20 days)
- 1,228,684
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.51
- 52-week range
- $160.36 – $261.00
- RSI (14 days)
- 59.1
- Volatility (1 year)
- 34.3%
- Relative volume
- 0.91×
- WACC
- 7.6%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIIB | S&P 500 | Difference | BIIB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.7% | -3.0% | +13.7 pts | ||
| 3 months | +20.3% | -2.8% | +23.1 pts | ||
| Year to date | +44.0% | +11.5% | +32.5 pts | ||
| 1 year | +53.8% | +13.5% | +40.4 pts | ||
| 3 years | +13.8% | +77.7% | −63.9 pts | +4.4% | +21.1% |
| 5 years | -6.3% | +72.6% | −78.9 pts | -1.3% | +11.5% |
| 10 years | -20.6% | +308.2% | −328.8 pts | -2.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biogen filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- News
- News
About Biogen
Biological Products, (No Diagnostic Substances)
Biogen is a biopharmaceutical enterprise that discovers, develops, and delivers therapies for individuals living with serious neurological conditions, rare disorders, and specialized immunological diseases. Its primary product lines encompass commercial treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, and amyotrophic lateral sclerosis, alongside collaborative therapies targeting Alzheimer's disease and postpartum depression. The company also commercializes advanced biosimilars for inflammatory diseases and holds business and financial rights to anti-CD20 oncological and immunological regimens. The business primarily serves patients affected by these complex conditions, facilitating product procurement, insurance navigation, and co-pay assistance.
Company profile, executives and historyBiogen stock: common questions
What is Biogen's stock price?
BIIB closed at $253.40 on Nov 13, 2026, up 1.17% on the day. Over the past 52 weeks it traded between $160.36 and $261.00.
What is Biogen's market cap?
Biogen was worth $37.46B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is BIIB's P/E ratio?
BIIB trades at 108.3 times earnings, based on diluted earnings per share of $2.34 over the twelve months to Sep 30, 2026.
How much revenue does Biogen make?
Biogen reported revenue of $10.30B for the twelve months to Sep 30, 2026, up 2.3% from a year earlier.
Does Biogen pay a dividend?
No. Biogen has not paid a cash dividend over the last twelve months.
When does Biogen report earnings next?
Biogen is expected to report Q4 FY2026 results on Jan 13, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BIIB stock performed over the past year?
Including dividends, BIIB returned +53.8% over the past year, against +13.5% for the S&P 500.
How many BIIB shares are sold short?
5M shares were sold short at the latest FINRA report, 3.70% of the float, or 4.0 days of average trading volume.
Who are Biogen's competitors?
Companies most similar to Biogen by business, industry and size include NBIX, AMGN, REGN, VRTX, MRNA.
See a number that looks wrong?